Want to see HK:1789 full AI Analyst Report?
Top Page
AK Medical Holdings Ltd.
(1789)
Select Model
Select Model
Rating:70Neutral
Price Target:
HK$5.50
▼(-6.94% Downside)
Action:Reiterated
Date:05/02/26
The score is driven primarily by solid financial fundamentals—strong margins and an exceptionally low-leverage balance sheet—tempered by uneven cash-flow conversion. Technical signals are somewhat weak/neutral (sub-50 RSI, low Stoch, below 20-day average), and valuation appears moderate (P/E ~17.3 with a modest ~1.14% yield).
Positive Factors
High profitability margins
Consistently high gross and operating margins indicate durable product-level economics and strong pricing power in orthopaedic implants. These margins support reinvestment, R&D and margins resilience across cycles, underpinning long-term cash generation and profitability sustainability.
Negative Factors
Cash-flow inconsistency
Intermittent cash conversion weakens the link between reported profits and real liquidity. Volatile operating cash can constrain investment timing and increase reliance on working-capital management, creating execution risk over the medium term despite strong accounting margins.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability margins
Consistently high gross and operating margins indicate durable product-level economics and strong pricing power in orthopaedic implants. These margins support reinvestment, R&D and margins resilience across cycles, underpinning long-term cash generation and profitability sustainability.
Read all positive factors
AK Medical Holdings Ltd. (1789) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.57B
Dividend Yield1.26%
Average Volume (3M)4.30M
Price to Earnings (P/E)15.0
Beta (1Y)1.07
Revenue Growth10.19%
EPS Growth23.70%
CountryHK
Employees950
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.30
Shares Outstanding1,124,616,700
10 Day Avg. Volume3,969,892
30 Day Avg. Volume4,297,109
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)1.97
Price to Sales (P/S)3.87
P/FCF Ratio18.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.40Price Target Upside42.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.36
Revenue Forecast (FY)HK$1.67B
AK Medical Holdings Ltd. Business Overview & Revenue Model
Company Description
AK Medical Holdings Limited, an investment holding enterprise, specializes in the research, development, production, and worldwide commercialization of orthopedic joint implants and related medical devices under the AK Medical brand. Its comprehen...
How the Company Makes Money
AK Medical makes money primarily by selling orthopaedic implant products and associated instruments to healthcare providers and distributors. Its core revenue stream comes from joint replacement implants (such as hip and knee systems) supplied for...
AK Medical Holdings Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.48B | 1.35B | 1.09B | 1.05B | 761.44M |
| Gross Profit | 897.39M | 808.19M | 674.49M | 636.43M | 499.19M |
| EBITDA | 465.33M | 371.66M | 323.34M | 322.87M | 184.33M |
| Net Income | 339.09M | 273.93M | 182.10M | 204.77M | 92.62M |
Balance Sheet | |||||
| Total Assets | 3.66B | 3.34B | 3.00B | 2.77B | 2.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.47B | 1.05B | 726.67M | 1.04B | 841.13M |
| Total Debt | 144.79M | 99.39M | 84.20M | 38.78M | 41.56M |
| Total Liabilities | 750.15M | 697.21M | 611.12M | 530.73M | 573.73M |
| Stockholders Equity | 2.91B | 2.64B | 2.39B | 2.24B | 2.03B |
Cash Flow | |||||
| Free Cash Flow | 316.09M | 289.11M | -162.14M | 121.20M | 100.39M |
| Operating Cash Flow | 419.03M | 451.07M | 33.94M | 242.92M | 176.62M |
| Investing Cash Flow | -316.18M | -393.35M | -318.15M | -82.29M | -297.10M |
| Financing Cash Flow | -83.26M | -39.43M | -14.02M | -36.80M | -100.70M |
AK Medical Holdings Ltd. Technical Analysis
Negative
5.91
Price Trends
5.94
Negative
5.94
Negative
5.78
Negative
Market Momentum
-0.27
Positive
27.37
Positive
12.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1789, the sentiment is Negative. The current price of 5.91 is above the 20-day moving average (MA) of 5.44, below the 50-day MA of 5.94, and above the 200-day MA of 5.78, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 27.37 is Positive, neither overbought nor oversold. The STOCH value of 12.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1789.
AK Medical Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$5.57B | 14.99 | 12.01% | 1.26% | 10.19% | 23.70% | |
61 Neutral | HK$5.92B | 37.29 | 4.06% | ― | 5.10% | -32.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$555.67M | -1.16 | -21.29% | ― | -34.96% | 42.74% | |
44 Neutral | HK$11.33B | 33.32 | 6.07% | ― | -3.62% | ― | |
43 Neutral | HK$22.61B | -84.92 | -52.78% | ― | 114.97% | 63.21% | |
40 Underperform | HK$1.38B | -0.76 | -7.01% | ― | ― | ― |
* Healthcare Sector Average
HK:1789
AK Medical Holdings Ltd.
5.19
-0.67
-11.36%
HK:0853
MicroPort Scientific
6.48
-2.28
-26.03%
HK:1302
LifeTech Scientific Corporation
1.42
-0.61
-30.05%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.14
-3.31
-74.38%
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
23.52
7.36
45.54%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.25
-1.33
-51.55%
AK Medical Holdings Ltd. Corporate Events
AK Medical Shareholders Approve All AGM Resolutions, Including Dividend and Issuance Mandates
Jun 17, 2026
AK Medical Holdings Ltd. reported that all resolutions at its 17 June 2026 annual general meeting were approved by shareholders via poll, including receipt of the 2025 audited accounts and declaration of a final dividend of HK11.8 cents per share....
AK Medical Details Structured Deposit Strategy with Bank of Communications
Jun 12, 2026
AK Medical Holdings Ltd. has disclosed that its group has been subscribing to principal-guaranteed structured time deposit products offered by Bank of Communications since 2018, using surplus cash to generate floating returns while preserving capi...
AK Medical Expands Share Buyback Plan to HK$500 Million
Jun 8, 2026
AK Medical Holdings Ltd. has announced that its board intends to exercise an existing share repurchase mandate, allowing the company to buy back up to 10% of its issued share capital, or 112,269,577 shares, on the Hong Kong Stock Exchange by 17 Ju...
AK Medical Boosts Surgical Robot Sales at Home and Abroad
May 28, 2026
AK Medical reported fresh momentum in its surgical robotics business, signing sales contracts in May 2026 for two K3 robotic systems with new overseas customers in Africa and South Asia. These deals build on earlier 2026 contracts, including a K3+...
AK Medical Sets 2026 AGM to Approve Dividend, Board Changes and Capital Mandates
Apr 28, 2026
AK Medical Holdings Ltd. has convened its annual general meeting for 17 June 2026 in Beijing, where shareholders will review the audited consolidated financial statements and related reports for the year ended 31 December 2025, and vote on a propo...
AK Medical Secures New Overseas Robot Orders as Dual-Brand Strategy Lifts Global Reach
Apr 8, 2026
AK Medical announced new overseas orders for its K3 and K3+ intelligent surgical robotic systems, including a recent sales contract for one unit and an indicated follow-on order, alongside several contracts signed from December 2025 to April 2026 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.